Author: NTIDC-EmpireDD

Gilead’s New Capsid Inhibitor in Early Trials
Post

Gilead’s New Capsid Inhibitor in Early Trials

Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.

Infectious Disease Medicine
Project

Infectious Disease Medicine

Infectious Diseases physicians are highly trained specialists, having spent 4 years completing medical school training, 3 years completing an Internal Medicine Residency Training Program and a minimum of 2 years of sub-specialty fellowship training in Infectious Diseases Medicine.

Antibiotic Therapy
Project

Antibiotic Therapy

"Traditional" prescription drug therapies commonly administered via infusion include antibiotic, antifungal, antiviral, chemotherapy, hydration, pain management and parenteral nutrition.

Gynaecological Clinic
Project

Gynaecological Clinic

Cum sociis natoque penatibus et magnis dis parturient montesmus. Pro vel nibh et elit mollis commodo et nec augueique

Ophthalmology Clinic
Project

Ophthalmology Clinic

Cum sociis natoque penatibus et magnis dis parturient montesmus. Pro vel nibh et elit mollis commodo et nec augueique

Cardiac Clinic
Project

Cardiac Clinic

Cum sociis natoque penatibus et magnis dis parturient montesmus. Pro vel nibh et elit mollis commodo et nec augueique

North Texas Infectious Diseases